Abstract:Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL) is an aggressive entity of non-Hodgkin's lymphoma with poor prognosis. ENKTL is sensitive to radiation but resistant to anthracycline-containing chemotherapy. This study aims to evaluate the efficacy of the chemoradiation therapy composed of DICE regimen and regional field radiation therapy in early stage ENTKL. In this study, we employed DICE regimen (dexamethasone, ifosfamide, mensa, cisplatin and etoposide) chemotherapy followed by regional field radiation therapy to treat patients with stages I ENKTL with risk factors in the upper aerodigestive tract and stage II ENKTL with cervical lymph nodes involved. The risk factors included elevated LDH, B symptom, ECOG≥2 and locally extensive disease involved more than two anatomic structures. Inductive chemotherapy was given 2 to 4 cycles and radiation was delivered with intensity-modulated radiation therapy (IMRT) to a prescribed dose of 50 Gy in 25 fractions. Treatment toxicities, locoregional, and systemic failure were observed, while treatment response and survival data were analyzed as well. In the cohort of 118 patients who met the enrollment criteria, 28.8% patients achieved complete response (CR) and 41.5% had partial response (PR) after DICE treatment. Subsequently, the CR rate climbed to 90.7%, with the PR rate of 6.8% after completion of definitive radiation therapy (RT). Patients tolerated chemotherapy and radiation therapy well. Grade II-III neutrophilic granulocytopenia was the main toxicity after chemotherapy. Long term mild xerostomia and hypogeusia after radiation therapy were observed in few patients. Among the patients who had CR after RT, 11 of them got local relapses in 3-46 months after the start of treatment, with the 5-year local control rate of 90.2%. Thirty-two patients developed systemic disseminations in 3-72 months after treatment. The most frequent recurrent site was skin, followed by organs in abdominopelvic cavity and central nervous system. Except for one patient died of diabetes and one died of secondary malignance, all the other 34 dead patients had distant metastasis or hemophagocytosis, with four concurrent local relapses. Totally, within a median follow-up time of 68 months (3-88 months), the 5-year overall survival (OS) and progression free survival (PFS) were 71.3% and 62.4%, respectively. In conclusion, DICE chemotherapy followed by involved field radiation therapy is a feasible and effective treatment for newly diagnosed stages I-II ENKTL.

The Promising Outcome with Simultaneous Integrated Boost Intensity Modulated Radiotherapy in Confined Nasal Extranodal NK/T-cell Lymphoma.

Promising clinical outcomes of sequential and "Sandwich" chemotherapy and extended involved-field intensity-modulated radiotherapy in patients with stage I E /II E extranodal natural killer/T-cell lymphoma.

Mild Toxicity and Favorable Prognosis of High–Dose and Extended Involved-Field Intensity-Modulated Radiotherapy for Patients with Early-Stage Nasal NK/T-Cell Lymphoma

[Outcome of Radiotherapy for Low-Risk Early-Stage Patients with Extranodal NK/T-cell Lymphoma, Nasal-Type].

Concurrent IMRT and weekly cisplatin followed by GDP chemotherapy in newly diagnosed, stage IE to IIE, nasal, extranodal NK/T-Cell lymphoma

Analysis of the treatment and prognosis of 266 cases of extranodal natural killer/T-cell lymphoma, nasal type in a single medical center

Radiation Therapy Alone Not Inferior to Chemoradiation in the Patients with Stage I Nasal Natural Killer/T-Cell Lymphoma

Preliminary Outcome of Concurrent Chemoradiation Therapy in Patients with Early Stage Extranodal Nasal Type NK/T-cell Lymphoma

Long-Term Efficacy of Sequential Dice Chemotherapy with Regional Field Radiation Therapy for Stages I-Ii Natural Killer/T-Cell Lymphoma, Nasal Type: Analysis of 118 Cases

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (NK/T)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study.

Extended Course and Increased Dose of Initial Chemotherapy for Extranodal Nasal Type Natural Killer/T (Nk/t)-Cell Lymphoma in Patients <60 Years Old: A Single-Center Retrospective Cohort Study

Radiotherapy followed by DICEP regimen in treatment of newly diagnosed, stage IE/IIE, extranodal NK/T-cell lymphoma patients.

Salvage Radiotherapy Improves Survival in Patients with Locoregionally Relapsed Stage IEIE-IIE Extranodal Natural Killer/t-Cell Lymphoma, Nasal Type

Treatment Outcome Of Radiotherapy Alone Versus Radiochemotherapy In Ie/Iie Extranodal Nasal-Type Natural Killer/T Cell Lymphoma: A Meta-Analysis

Combined chemotherapy and external beam radiation for stage IE and IIE natural killer T-cell lymphoma of nasal cavity.

Radiotherapy As Primary Treatment for Stage IE and IIE Nasal Natural Killer/T-Cell Lymphoma

Chemotherapy combined with high-dose extended-field radiotherapy for stage I extranodal nasal-type natural killer/T-cell lymphoma

Deep Remission from Induction Chemotherapy Predicts Favorable Long-Term Survivals in Early Stage Extranodal Nasal NK/T-cell Lymphoma Receiving Sequential Chemotherapy and Radiation.

Treatment outcomes and prognostic analysis of elderly patients with extranodal natural killer/T-cell lymphoma, nasal type: a retrospective analysis

Radiotherapy alone with curative intent in patients with stage I extranodal nasal-type NK/T-cell lymphoma.

Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in the Treatment of Stage IE/IIE Extranodal Natural Killer/t Cell Lymphoma, Nasal Type: 13-Year Follow-Up in 135 Patients.